Lexicon Pharmaceuticals (LXRX) Trading Down 7.9% After Analyst Downgrade
Lexicon Pharmaceuticals, Inc. (NASDAQ:LXRX)’s share price traded down 7.9% during mid-day trading on Monday after ValuEngine downgraded the stock from a hold rating to a sell rating. The company traded as low as $4.25 and last traded at $5.71. 65,709 shares were traded during mid-day trading, a decline of 95% from the average session volume of 1,361,117 shares. The stock had previously closed at $6.20.
A number of other equities analysts also recently issued reports on the company. Gabelli upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Monday. Stifel Nicolaus dropped their price target on Lexicon Pharmaceuticals from $14.00 to $10.00 and set a “buy” rating on the stock in a research note on Monday. Needham & Company LLC reiterated a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday. BidaskClub upgraded Lexicon Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Thursday, March 14th. Finally, Wedbush lifted their target price on Lexicon Pharmaceuticals from $36.00 to $38.00 and gave the company an “outperform” rating in a research report on Monday, March 4th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company. The stock has an average rating of “Hold” and an average target price of $17.13.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in LXRX. Clearbridge Investments LLC lifted its position in Lexicon Pharmaceuticals by 974,268.4% during the third quarter. Clearbridge Investments LLC now owns 1,295,910 shares of the biopharmaceutical company’s stock valued at $13,827,000 after purchasing an additional 1,295,777 shares in the last quarter. D. E. Shaw & Co. Inc. lifted its position in Lexicon Pharmaceuticals by 181.5% during the fourth quarter. D. E. Shaw & Co. Inc. now owns 268,476 shares of the biopharmaceutical company’s stock valued at $1,783,000 after purchasing an additional 173,096 shares in the last quarter. Norges Bank purchased a new position in Lexicon Pharmaceuticals during the fourth quarter valued at $1,005,000. First Trust Advisors LP purchased a new position in Lexicon Pharmaceuticals during the third quarter valued at $1,525,000. Finally, Two Sigma Investments LP raised its holdings in Lexicon Pharmaceuticals by 70.0% during the fourth quarter. Two Sigma Investments LP now owns 313,877 shares of the biopharmaceutical company’s stock valued at $2,084,000 after acquiring an additional 129,215 shares during the period. Institutional investors own 99.16% of the company’s stock.
Lexicon Pharmaceuticals (NASDAQ:LXRX) last posted its quarterly earnings results on Wednesday, March 13th. The biopharmaceutical company reported ($0.16) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.28) by $0.12. The business had revenue of $17.10 million for the quarter, compared to analysts’ expectations of $13.33 million. Lexicon Pharmaceuticals had a negative return on equity of 911.43% and a negative net margin of 192.53%. The business’s quarterly revenue was down 49.7% on a year-over-year basis. During the same period last year, the firm earned ($0.27) earnings per share. Sell-side analysts expect that Lexicon Pharmaceuticals, Inc. will post -0.26 EPS for the current fiscal year.
TRADEMARK VIOLATION WARNING: “Lexicon Pharmaceuticals (LXRX) Trading Down 7.9% After Analyst Downgrade” was reported by Watch List News and is owned by of Watch List News. If you are reading this news story on another publication, it was copied illegally and republished in violation of international copyright law. The original version of this news story can be viewed at https://www.watchlistnews.com/lexicon-pharmaceuticals-lxrx-trading-down-7-9-after-analyst-downgrade/2919885.html.
About Lexicon Pharmaceuticals (NASDAQ:LXRX)
Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the development and commercialization of pharmaceutical products for the treatment of human diseases. The company offers XERMELO, an orally-delivered small molecule drug candidate for the treatment of carcinoid syndrome diarrhea in combination with somatostatin analog therapy in adults.
See Also: Why are gap-down stocks important?
Receive News & Ratings for Lexicon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexicon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.